arrow_back Back to App

Mandatory Coverage for Scalp Cooling Items in Chemotherapy by Health Insurance

This new act aims to ensure that health insurance plans, including federal programs like Medicare and Medicaid, cover the costs of scalp cooling caps used to prevent hair loss during chemotherapy. This means individuals undergoing cancer treatment will have easier access to this therapy, potentially improving their comfort and quality of life during a challenging treatment period.
Key points
Health insurance, including group and individual plans, will be required to cover scalp cooling items starting January 1, 2023.
Federal programs such as Medicare, Medicaid, CHIP, FEHBP, TRICARE, and VA will also be mandated to fund these devices.
Out-of-pocket costs (e.g., copayments, deductibles) for scalp cooling items will be the same as for intravenous or injectable anticancer drugs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7322
Sponsor: Rep. DeLauro, Rosa L. [D-CT-3]
Process start date: 2022-03-31
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Access to Scalp Cooling Therapy Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7322.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-31.

What are the main provisions?

Key points include:

  • Health insurance, including group and individual plans, will be required to cover scalp cooling items starting January 1, 2023.
  • Federal programs such as Medicare, Medicaid, CHIP, FEHBP, TRICARE, and VA will also be mandated to fund these devices.
  • Out-of-pocket costs (e.g., copayments, deductibles) for scalp cooling items will be the same as for intravenous or injectable anticancer drugs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. DeLauro, Rosa L. [D-CT-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health